<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 26, 2018 (HealthDay News) — Use of an automated, closed-loop insulin delivery system results in significantly better glycemic control than conventional subcutaneous insulin therapy among patients with type 2 diabetes receiving noncritical care, according to a study published online June 25 in the New England Journal of Medicine<\/i> to coincide with the annual meeting of the American Diabetes Association, held from June 22 to 26 in Orlando, Florida.<\/p>\n
Lia Bally, Ph.D., from the University of Bern in Switzerland, and colleagues randomized adults with type 2 diabetes who required subcutaneous insulin therapy to receive closed-loop insulin delivery (70 patients) or conventional subcutaneous insulin therapy (66 patients).<\/p>\n
The researchers found that the mean percentage of time that the sensor glucose measurement was in the target range of 100 to 180 mg\/dL was 65.8\u00b116.8 percent and 41.5\u00b116.9 percent in the closed-loop and control groups, respectively; values above the target range were found in 23.6\u00b116.6 percent and in 49.5\u00b122.8 percent of the patients, respectively. The mean glucose level was 154 mg\/dL and 188 mg\/dL in the closed-loop and control groups, respectively. No significant difference was seen between the groups in the duration of hypoglycemia or the amount of insulin delivered.<\/p>\n
“Among inpatients with type 2 diabetes receiving noncritical care, the use of an automated, closed-loop insulin-delivery system resulted in significantly better glycemic control than conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia,” the authors write.<\/p>\n
Abbott Diabetes Care supplied discounted equipment. Several authors disclosed financial ties to pharmaceutical and medical device companies, including Abbott, and two authors hold patents for closed-loop insulin delivery systems.<\/p>\n
Abstract\/Full Text<\/a> <\/i><\/p>\n
More Information<\/a><\/p>\n